Skip to main content
Premium Trial:

Request an Annual Quote

Cellgen, Genomics Testing Cooperative Form Cancer Companion Diagnostic Alliance

NEW YORK (GenomeWeb) — Cellgen Diagnostics said today that it has partnered with molecular testing firm Genomic Testing Cooperative (GTC) to offer companion diagnostic development services for cancer immunotherapy developers.

Under the terms of the deal, the companies will combine Cellgen's cartridge assay-based molecular diagnostics platform with GTC's biomarker discovery technologies to create a service for biomarker discovery and validation, as well as in vitro diagnostic companion assay development, for pharmaceutical industry customers.

According to Cellgen, its so-called Immune Panel assays enable patient stratification and therapeutic response monitoring, while GTC's technologies can be used to profile the tumor microenvironment to create patient phenotypic profiles.

The companies — both of which are based in Irvine, California — intend to first focus on next-generation sequencing applications in early-stage clinical programs. Additional terms were not disclosed.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.